Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

NCT02508376 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

NIH

Sponsor class

Conditions

Tuberculosis

Interventions

OTHER: AP10-602
BIOLOGICAL: GLA-SE
BIOLOGICAL: ID93

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)